24 results
8-K
EX-99.2
AXLA
Axcella Health Inc.
29 Sep 22
Regulation FD Disclosure
9:15am
cycle AA Metabolism AXA1125 AXA1125 GLP - 1 SCD1 FGF21 THR - β PPAR FXR Single Targets Single Targets Single Targets TGF β Cyclophilin CCR2/5 … across NASH Disease Drivers Fibrosis Inflammation Metabolism AXA1125 AXA1125 AXA1125 GLP - 1 SCD1 FGF21 THR - β PPAR FXR Single Targets Single Targets
8-K
EX-99.2
AXLA
Axcella Health Inc.
2 Aug 22
Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID
4:06pm
and data to study its potential in Long Covid
© 2022 Axcella Therapeutics. All rights reserved. 35 AXA1125 Targets Key Environment, Inflammation
8-K
EX-99.1
29quhft
10 Jan 22
Other Events
8:00am
8-K
EX-99.2
eut88o0cp1nemgp
6 May 21
Axcella Reports First Quarter Financial Results and Provides Business Update
7:51am
10-K
69pqbg 90xdkt2q1q35
23 Mar 20
Annual report
4:12pm
424B4
h7qsy2 98uv7
9 May 19
Prospectus supplement with pricing info
4:29pm
S-1/A
EX-10.4
8zqqw436zmzp 6lmtu9
30 Apr 19
IPO registration (amended)
6:06am